19 March 2020

Radboudumc and UMC Utrecht will investigate whether health care workers are better protected against the coronavirus after a vaccination against tuberculosis (BCG vaccine). This vaccine does not directly protect against the coronavirus, but provides a boost to the immune system, which may lead to improved protection against the coronavirus and a milder infection.
 
The coronavirus (COVID-19) infects more and more people. This also applies to hospital staff, which can cause capacity problems in the healthcare system. There is currently no vaccine against the virus and it takes time before a vaccine will become available. In the United States, for example, an investigation into an mRNA vaccine has just started and an investigation into a DNA vaccine will follow soon, but even with good results it will take time before such a vaccine is available.
 
Not directed against corona
Radboudumc and UMC Utrecht are now investigating whether hospital staff can be protected by a vaccine against tuberculosis. This BCG vaccine (Bacillus Calmette-Guérin) does not directly target the coronavirus, but it boosts the immune system. This boost may provide additional protection against a coronavirus infection, which may result in fewer people to suffer from the virus and also make the infection milder.
 
More protection, less downtime?
Previous research shows that such a boost of the immune system with BCG provides some protection against influenza, but it is not known whether this also applies to other infections such as corona. "That is exactly the reason for this research," says Mihai Netea, professor of experimental internal medicine. "If during this epidemic fewer people in the BCG-vaccinated group would drop out due to illness, this would be an encouraging result."
 
Thousand employees
Marc Bonten, professor of molecular epidemiology of infectious diseases at the UMC Utrecht, has initiated this research together with Netea. The study has now been approved by the Medical Ethics Review Committee (METC). "We are in the middle of the outbreak, so we want to have the results of this study as soon as possible," says Bonten. “A total of 1000 employees can participate at Radboudumc, UMC Utrecht, but also in other hospitals. Half of them will receive the BCG vaccine, the other half a placebo. If it turns out that the vaccine does indeed provide extra protection, we can also offer it to other employees.”
 
 

Related news items


BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea

11 August 2020

The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.

read more

650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

read more

Increased role of patients after bowel cancer treatment

30 July 2020

Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.

read more

ERC Proof of Concept grant received by Ronald van Rij

30 July 2020

Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.

read more

Hypatia fellowship Call is open

30 July 2020

The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.  

read more

Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation. 

29 July 2020

These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.

read more